HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Kevin B Walsh Selected Research

Cytokines

1/2020Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia.
11/2018The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors.
6/2014Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy.
3/2014Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection.
1/2013Dissecting influenza virus pathogenesis uncovers a novel chemical approach to combat the infection.
1/2013Three phases of CD8 T cell response in the lung following H1N1 influenza infection and sphingosine 1 phosphate agonist therapy.
9/2011Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection.
2/2010IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection.
2/2009A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Kevin B Walsh Research Topics

Disease

14Infections
06/2014 - 03/2008
7Cytokine Release Syndrome
06/2014 - 07/2011
7Virus Diseases (Viral Diseases)
01/2013 - 03/2008
3Neoplasms (Cancer)
01/2020 - 11/2018
3Human Influenza (Influenza)
01/2013 - 10/2011
2Inflammation (Inflammations)
06/2014 - 01/2013
2Lung Injury
03/2014 - 07/2011
2Liver Diseases (Liver Disease)
03/2008 - 07/2007
1Hypoxia (Hypoxemia)
01/2020
1Lung Diseases (Lung Disease)
06/2014
1Respiratory Tract Diseases (Respiratory Tract Disease)
06/2014
1Edema (Dropsy)
01/2013
1Persistent Infection
06/2012
1Autoimmune Diseases (Autoimmune Disease)
10/2011
1Immune System Diseases (Immune Disorders)
07/2011
1Lymphopenia (Lymphocytopenia)
02/2010
1Encephalitis (Encephalitis, Rasmussen)
03/2008
1Acute Disease
03/2008
1Hepatitis
07/2007

Drug/Important Bio-Agent (IBA)

9CytokinesIBA
01/2020 - 02/2009
6Antiviral Agents (Antivirals)IBA
03/2014 - 03/2008
5Sphingosine-1-Phosphate ReceptorsIBA
06/2014 - 02/2010
5SphingosineIBA
01/2013 - 09/2008
4sphingosine 1-phosphate (sphingosine-1-phosphate)IBA
06/2014 - 10/2011
3LigandsIBA
03/2008 - 07/2007
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2014 - 03/2008
2Interferon-gamma (Interferon, gamma)IBA
06/2014 - 03/2008
2ChemokinesIBA
01/2013 - 01/2013
2Phosphates (Orthophosphate)IBA
01/2013 - 09/2008
2CXC ChemokinesIBA
03/2008 - 07/2007
2NK Cell Lectin-Like Receptor Subfamily KIBA
03/2008 - 03/2008
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2020
1AntibodiesIBA
12/2018
1Neutralizing AntibodiesIBA
06/2014
1SolutionsIBA
03/2014
1Oseltamivir (Tamiflu)FDA Link
03/2014
1VaccinesIBA
03/2014
1Toll-Like Receptor 7IBA
06/2012
1Viral RNAIBA
06/2012
1Pharmaceutical PreparationsIBA
10/2011
1AUY 954IBA
02/2010
1Fingolimod Hydrochloride (FTY720)FDA Link
02/2010
1Interleukin-10 (Interleukin 10)IBA
02/2010
1EstersIBA
09/2008
1Chemotactic FactorsIBA
03/2008
1PerforinIBA
03/2008
1Alanine Transaminase (SGPT)IBA
07/2007

Therapy/Procedure

7Therapeutics
01/2020 - 07/2011
1Immunotherapy
01/2020